Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

FDA Accepts To Review Verona Pharma's New Drug Application For Ensifentrine For Maintenance Treatment Of Chronic Obstructive Pulmonary Disease, With PDUFA Target Action Date Of June 26, 2024

Author: Benzinga Newsdesk | September 11, 2023 02:35am

Posted In: VRNA